Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Rad LaboratoriesFRA:BUWA +1.43%75 Return-on-Tangible-Asset is 16.03% as of Jun. 2026, which is 171% above its 10-year median of 5.91. GuruFocus rates FRA:BUWA with a GF Score™ of 75/100 and a GF Value™ of €276.56 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 56.14% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bio-Rad Laboratories's annualizedNet Income for the quarter that ended in Jun. 2026 was €1,290 Mil. Bio-Rad Laboratories's average total tangible assets for the quarter that ended in Jun. 2026 was €8,043 Mil. Therefore, Bio-Rad Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 16.03%.
The historical rank and industry rank for Bio-Rad Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
FRA:BUWA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -24.21 Med: 5.91 Max: 37.99
Current: 2.4
During the past 13 years, Bio-Rad Laboratories's highest Return-on-Tangible-Asset was 37.99%. The lowest was -24.21%. And the median was 5.91%.
FRA:BUWA's Return-on-Tangible-Asset is ranked better than 56.14% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.74
vs FRA:BUWA: 2.40
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bio-Rad Laboratories Return-on-Tangible-Asset Related Terms
Bio-Rad Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs GKOS, BRKR, GMED: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.03% mean?
Bio-Rad Laboratories (FRA:BUWA) has a Return-on-Tangible-Asset of 16.03% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bio-Rad Laboratories and its competitors. This is 171% above median its historical median of 5.91. According to the industry distribution chart, Bio-Rad Laboratories ranks #375 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 43.9%.
Is Bio-Rad Laboratories' Return-on-Tangible-Asset too high?
Bio-Rad Laboratories' current Return-on-Tangible-Asset of 16.03% is 171% above median its 10-year median of 5.91. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.74. Bio-Rad Laboratories' value of 16.03% is 2066.2% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #375 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Return-on-Tangible-Asset compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #375 out of 855 companies for Return-on-Tangible-Asset. This puts Bio-Rad Laboratories in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.74. Bio-Rad Laboratories' value of 16.03% is 2066.2% above this benchmark. While the company's 10-year median is 5.91 vs. the industry median of 0.74, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.74, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current Return-on-Tangible-Asset of 16.03% is 2066.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current Return-on-Tangible-Asset is 16.03%, which is 171% above median its own 10-year median of 5.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Overvalued. The stock's GF Value™ is €276.56, compared to a current price of €312.20 — trading 12.9% above its estimated fair value. The current Return-on-Tangible-Asset is 16.03%, which is 171% above median its 10-year median of 5.91 and 2066.2% above the Medical Devices & Instruments industry median of 0.74. Bio-Rad Laboratories' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Return-on-Tangible-Asset is 16.03% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued.
The current stock price of €312.20 is trading 12.9% above its estimated GF Value™ of €276.56.
GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.
Key valuation signals for FRA:BUWA:
Return-on-Tangible-Asset: 16.03% (171% above median its 10-year median of 5.91)
GF Value™: €276.56 vs. price of €312.20 (12.9% above fair value)
Industry Position: 2066.2% above the Medical Devices & Instruments median (#375 of 855)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
75GF Score
Get the complete analysis for FRA:BUWA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
